EKTAB N Stock Overview
A medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 4/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Elekta AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 126.63 |
52 Week High | SEK 145.92 |
52 Week Low | SEK 116.44 |
Beta | 1.11 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -57.61% |
5 Year Change | n/a |
Change since IPO | -56.44% |
Recent News & Updates
Recent updates
Shareholder Returns
EKTAB N | MX Medical Equipment | MX Market | |
---|---|---|---|
7D | 0% | 0% | 0% |
1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how EKTAB N performed against the MX Medical Equipment industry.
Return vs Market: Insufficient data to determine how EKTAB N performed against the MX Market.
Price Volatility
EKTAB N volatility | |
---|---|
EKTAB N Average Weekly Movement | n/a |
Medical Equipment Industry Average Movement | 0% |
Market Average Movement | 0% |
10% most volatile stocks in MX Market | 0% |
10% least volatile stocks in MX Market | 0% |
Stable Share Price: EKTAB N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine EKTAB N's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1972 | 4,651 | Gustaf Salford | elekta.com |
Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software.
Elekta AB (publ) Fundamentals Summary
EKTAB N fundamental statistics | |
---|---|
Market cap | Mex$45.33b |
Earnings (TTM) | Mex$2.33b |
Revenue (TTM) | Mex$32.45b |
19.4x
P/E Ratio1.4x
P/S RatioIs EKTAB N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EKTAB N income statement (TTM) | |
---|---|
Revenue | SEK 18.12b |
Cost of Revenue | SEK 11.32b |
Gross Profit | SEK 6.80b |
Other Expenses | SEK 5.50b |
Earnings | SEK 1.30b |
Last Reported Earnings
Apr 30, 2024
Next Earnings Date
Aug 28, 2024
Earnings per share (EPS) | 3.41 |
Gross Margin | 37.55% |
Net Profit Margin | 7.19% |
Debt/Equity Ratio | 55.0% |
How did EKTAB N perform over the long term?
See historical performance and comparisonDividends
3.6%
Current Dividend Yield70%
Payout RatioDoes EKTAB N pay a reliable dividends?
See EKTAB N dividend history and benchmarksElekta dividend dates | |
---|---|
Ex Dividend Date | Sep 06 2024 |
Dividend Pay Date | Sep 12 2024 |
Days until Ex dividend | 127 days |
Days until Dividend pay date | 121 days |
Does EKTAB N pay a reliable dividends?
See EKTAB N dividend history and benchmarksCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/08/10 05:27 |
End of Day Share Price | 2024/05/13 00:00 |
Earnings | 2024/04/30 |
Annual Earnings | 2024/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Elekta AB (publ) is covered by 39 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Sumit Sayal | AlphaValue |
Alexander Kleban | Barclays |
Hassan Al-Wakeel | Barclays |